Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 790
Clinical Pharmacology & Biopharmaceutics received 790 citations as per Google Scholar report
Clinical Pharmacology & Biopharmaceutics peer review process verified at publons
Indexed In
- CAS Source Index (CASSI)
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Genamics JournalSeek
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Current Clinical Indications of Immunomodulators
6th European Biopharma Congress
Bimal Roy Krishna
Touro University, USA
Keynote: Clin Pharmacol Biopharm
Abstract
Immunomodulators have shown great promise in regard to prevention and treatment of various disorders ranging from autoimmune, inflammation, rheumatoid arthritis, Crohns Disease and infectious diseases. Several agents exist with different mechanisms of action, indications and side effect profiles. The two general categories are Immunosuppressive and Immunostimulatory agents. The goal has been to increase immune system specificity while minimizing toxicity peripherally and to other organs. Infectious diseases are considered immunological disorders and neoplastic diseases are involved in an immunosuppressive state. Immunomodulators are able to stimulate natural and defensive mechanisms which are of potential clinical benefit. While they are highly beneficial, their side effects and toxicity profile can often limit their use. There are also potential drug interactions. This presentation summarizes a number of immunomodulators with their clinical indications, mechanism of action and toxicity profiles.Biography
Bimal Roy Krishna is currently Professor and Director of Pharmacology at the College of Osteopathic Medicine, Touro University in Nevada. He obtained a Bachelor of Science (First Class Honors) in Pharmacology and Physiology and a Doctor of Philosophy, Medicine (OB/GYN/Pharmacology) from Monash University in Australia. He also teaches for the Step 1 USMLE and COMLEX reviews for Kaplan Medical throughout the United States and in UAE, Europe, Saudi Arabia, India, Mexico and the Caribbean. He has been teaching online for Kaplan University for over seven years. He has contributed to numerous publications and is a Member of a number of organizations including Fellow-American College of Clinical Pharmacology. His research background is in Maternal and Neonatal Pharmacology, specifically looking at materno-fetal transfer utilizing the perfused human placental and cultured syncytiotrophoblast model. Complementary and Alternative Medicine is another area of his interest.
E-mail: roy.krishna@tun.touro.edu
